Reviewing GBS (NYSE:GBS) and Spectral Medical (OTCMKTS:EDTXF)

Volatility & Risk

GBS has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Spectral Medical has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Valuation & Earnings

This table compares GBS and Spectral Medical”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GBS $440,000.00 47.38 -$8.31 million ($0.56) -2.50
Spectral Medical $1.18 million 81.93 -$11.60 million ($0.07) -4.86

GBS has higher earnings, but lower revenue than Spectral Medical. Spectral Medical is trading at a lower price-to-earnings ratio than GBS, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GBS and Spectral Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GBS N/A -85.64% -54.42%
Spectral Medical -1,245.87% N/A -351.89%

Institutional and Insider Ownership

2.8% of GBS shares are held by institutional investors. 0.3% of GBS shares are held by insiders. Comparatively, 1.5% of Spectral Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

GBS beats Spectral Medical on 6 of the 11 factors compared between the two stocks.

About GBS

(Get Free Report)

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

About Spectral Medical

(Get Free Report)

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

Receive News & Ratings for GBS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GBS and related companies with MarketBeat.com's FREE daily email newsletter.